Key facts
- DEKA Biosciences’s last known valuation is $36.0M (Feb 2023).
- It has raised $104.2M across 2 recorded rounds; the latest was Early Stage VC ($29.9M) in Feb 2023.
- Notable investors include Alexandria Venture Investments, Echo Investment Capital, Viva BioInnovator, MPM BioImpact, ATEM Capital — 10 tracked in total.
- DEKA Biosciences has filed 2 Form Ds with the SEC since 2021, most recently Dec 2023 ($29.9M sold to 33 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for DEKA Biosciences
Funding rounds
2 roundsAbout DEKA Biosciences
Operator of a biotechnology company intended to develop and deliver life-changing medicines for cancer and inflammatory diseases. The company's therapies have disease-specific applications that maximize patient benefits through improved pharmacokinetics/pharmacodynamics (PK/PD) function via targeted delivery of dual and complementary cytokines to affected tissues or cells, enabling patients with curative treatment options for cancer, autoimmune and infectious diseases.
- Sector
- Healthcare
- HQ
- Germantown, MD, United States
- Founded
- 2019
- Employees
- 20
- Website
- dekabiosciences.com/
- Ownership
- Privately Held (backing)
DEKA Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DEKA Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DEKA Biosciences in its N-PORT filings yet. We sweep new filings monthly.